证券日报网讯1月20日，梅花生物（600873）在互动平台回答投资者提问时表示，公司发展战略为：1) 聚焦主业高质量增长，致力于成为合成生物学领军企业，做最具竞争力的行业龙头，做氨基酸行业智慧 工厂、"灯塔工厂"；2)以技术引领和管理领先为双驱动，研发、供产销及各职能部门多头并进，加固公 司护城河；3)坚持创造分享，坚持客户为中心，坚持诚信为本，具体业绩情况请关注公司定期报告。 ...

（文章来源：证券日报） 证券日报网讯 1月20日，梅花生物在互动平台回答投资者提问时表示，公司2026年员工持股计划的购买 价格为公司股票市价。 ...

证券日报网讯 1月20日，梅花生物在互动平台回答投资者提问时表示，公司整体海外收入占比约30%； 公司在欧盟地区的销售以直销为主。 （文章来源：证券日报） ...

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can help optimize industrial structures and transform economic models [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current status and trends in biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this field [5]. Group 2: Policy Landscape - The white paper discusses major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. Group 3: Industry Map and Applications - It provides a comprehensive map of the Chinese biomanufacturing industry and analyzes the industry chain along with key application directions, including biomanufacturing in pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The report identifies ten leading enterprises in the Chinese biomanufacturing sector, detailing their contributions and roles within the industry [5][6]. Group 5: Company Strategies - It outlines the synthetic biology strategies of 15 listed companies, summarizing their development approaches and corresponding popular products [5][6]. Group 6: Investment and Challenges - The white paper reviews the investment and financing situation in domestic synthetic biology from 2024 to mid-2025 and discusses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [5][6].

Group 1 - The core viewpoint of the articles highlights the positive trend in pig prices driven by the consumption peak season, with the average price of lean pigs reaching 12.49 CNY/kg, a 2.6% increase month-on-month [1] - The stock performance of the livestock breeding index shows mixed results, with leading stocks like Ruisheng Biological rising by 9.91% and the Livestock ETF priced at 0.68 CNY [1] - The overall pig farming sector is experiencing a "tug-of-war" state, where companies with cost advantages are more resilient in competition [1] Group 2 - According to Huaxi Securities, the average price of external three yuan pigs reached 12.7 CNY/kg, a week-on-week increase of 1.26%, indicating a steady rise in pig prices [2] - As of the end of October, the number of breeding sows in China was 39.9 million, a decrease of 1.1% month-on-month, reflecting ongoing adjustments in pig production capacity [2] - The self-breeding and external purchasing pig farming models have turned profitable, with profits of 7.39 CNY/head and 2.31 CNY/head respectively [2] Group 3 - The CSI Livestock Breeding Index (930707) includes companies involved in livestock feed, veterinary drugs, and livestock farming, reflecting the overall performance of listed companies in the livestock sector [2] - The top ten weighted stocks in the CSI Livestock Breeding Index account for 67.66% of the index, with major companies including Muyuan Foods, Haida Group, and Wens Foodstuffs [2]

Core Viewpoint - Meihua Biological Technology Group Co., Ltd. has shown a positive stock performance with a 6.42% increase year-to-date and a significant rise in net profit, indicating potential growth in the amino acid market [1][2]. Company Overview - Meihua Biological, established on February 9, 1995, and listed on February 17, 1995, is located in Langfang, Hebei Province. The company specializes in the research, production, and sales of amino acid products [1]. - The main revenue sources are feed amino acids (46.09%), flavor enhancers (29.04%), by-products (15.38%), other products (7.47%), and pharmaceutical amino acids (2.01%) [1]. Financial Performance - For the period from January to September 2025, Meihua Biological reported a revenue of 18.215 billion yuan, a year-on-year decrease of 2.49%, while net profit attributable to shareholders increased by 51.61% to 3.025 billion yuan [2]. - The company has distributed a total of 12.047 billion yuan in dividends since its A-share listing, with 4.075 billion yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 13.10% to 66,700, while the average number of circulating shares per person decreased by 13.09% to 42,058 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 18.336 million shares, and new entrants like Guotai CSI Livestock Breeding ETF and Southern S&P China A-share Large Cap Dividend Low Volatility 50 ETF [3].

Group 1 - The company is integrating its acquired overseas business according to its established plan, with specific performance details available in regular reports [1] - The acquired assets primarily consist of pharmaceutical amino acid products, including arginine and histidine, for which domestic production bases have initiated project preparations [1]

Core Insights - The article presents the top 20 stocks in the S&P China A-Share Dividend Opportunity Index (CSPSADRP) based on their daily and year-to-date performance as of January 15, 2026, highlighting significant gainers and their dividend yields [1][5]. Group 1: Stock Performance - The top performer is Aotewi (688516.SH) with a daily increase of 8.15% and a year-to-date increase of 32.30%, along with a dividend yield of 3.80% [1][5]. - Weichai Power (000338.SZ) ranks second with a daily rise of 4.18% and a year-to-date increase of 17.44%, offering a dividend yield of 3.62% [1][5]. - Action Education (605098.SH) follows with a daily gain of 4.01% and a year-to-date increase of 11.71%, featuring a dividend yield of 5.02% [1][5]. Group 2: Dividend Yields - The highest dividend yield among the top 20 stocks is from Jichuan Pharmaceutical (600566.SH) at 7.99%, with a daily increase of 1.57% and a year-to-date increase of 0.84% [1][5]. - Other notable dividend yields include Oppein Home (603833.SH) at 6.85% and Qianjiang Motorcycle (000913.SZ) at 5.67% [1][5]. Group 3: Market Trends - The article notes the formation of a MACD golden cross signal, indicating a positive trend in the stock market, particularly for the highlighted stocks [4][8].

Group 1 - The livestock farming industry in China is undergoing a significant transformation, with the Ministry of Agriculture and Rural Affairs and the National Development and Reform Commission calling for capacity reduction and operational control as of September 2025 [1][19] - The pig cycle typically follows a pattern of price fluctuations, with each upward cycle lasting about 1-2 years and downward cycles lasting about 1-3 years, indicating potential for price increases following supply reductions [1][19] - Current signals suggest that the pig farming industry is at a relatively low valuation, with indications that capacity reduction may accelerate [1][19] Group 2 - The CSI Livestock Farming Industry Index, launched on December 31, 2021, includes 50 listed companies in sectors such as livestock products, animal health, feed, meat products, and dairy products, serving as a benchmark for the overall performance of the livestock farming sector [2][20] - The index has a base point of 1000 and aims to reflect the core fluctuations of the livestock farming industry, with a high concentration of leading companies [4][23] - The top five constituent stocks account for 50.1% of the index, while the top ten account for 67.6%, indicating a significant concentration advantage in the industry [4][23] Group 3 - The CSI Livestock Farming Industry Index has outperformed its peers by 5 percentage points since its inception, with a current PE (TTM) ratio of 19.02, indicating a low valuation at the bottom of the cycle and potential for valuation recovery [6][26] - The index's historical performance has shown significant volatility due to the cyclical nature of the livestock farming industry [6][26] - The index is designed to provide a high-purity tool for tracking the cyclical movements of pig farming, benefiting from the resilience and profit elasticity of leading enterprises during current cost-focused cycles [4][23] Group 4 - The top ten constituent stocks of the index include major players such as Muyuan Foods (15.6% weight), Wens Foodstuff Group (14.7%), and Haida Group (9.1%), highlighting the dominance of leading companies in the livestock sector [25] - The index is positioned to benefit from ongoing policy incentives and signals of cyclical reversal, making it an attractive investment option for those optimistic about the long-term development of the livestock farming industry [33]

Group 1 - The company, Meihua Biological, provided detailed information regarding tax policies in its annual report [2] - Amino acid-related products are eligible for export tax rebate policies according to national tax regulations [2]